Summary
Biogen Idec Inc. (BIIB) filed an 8-K on January 28, 2013, primarily to report its financial results for the full year and fourth quarter ended December 31, 2012. The company issued a press release (Exhibit 99) detailing these results, which investors should review for operational performance and financial condition updates. This filing is crucial for understanding Biogen's recent performance and its trajectory heading into the new fiscal year. While the provided text is an excerpt, it confirms the release of the company's year-end and quarterly financial data. Investors are advised to consult the full press release for specific figures regarding revenue, profitability, and any forward-looking statements or management commentary on the company's outlook. The filing also notes that the press release is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, a standard disclosure for such reports.
Key Highlights
- 1Biogen Idec Inc. (BIIB) announced its financial results for the full year and fourth quarter of 2012 via an 8-K filing on January 28, 2013.
- 2The primary purpose of the 8-K was to furnish a press release containing the company's operational and financial condition results.
- 3Investors can find detailed financial performance data in the press release, which is incorporated by reference as Exhibit 99.
- 4The filing serves as a key update on the company's performance for the period ending December 31, 2012.
- 5The press release is furnished under Item 2.02 and is not considered "filed" under Section 18 of the Exchange Act, limiting its liability implications.